Friday, 20 November 2026European Markets

GENSIGHT BIOLOGICS Stock Rise On Thursday, Outperforms Market

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Loading stream...

(vianews) - the market ended the session with gensight biologics (sight.pa) jumping 9.14% to €0.37 on thursday, after five successive sessions in a row of losses. cac 40 jumped 0.71% to €7,665.63, following the last session's downward trend on what was a somewhat up trend exchanging session today.

gensight biologics's last close was €0.34, 91.26% below its 52-week high of €3.88.

about gensight biologics

gensight biologics s.a., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. the company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. its lead product candidates include lumevoq (gs010), a recombinant aav2-based gene therapy, which is in phase iii clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated nd4 gene; and gs030, which is in phase i/ii clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. the company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. the company was incorporated in 2012 and is headquartered in paris, france.

earnings per share

as for profitability, gensight biologics has a trailing twelve months eps of €-0.63.

volume

today's last reported volume for gensight biologics is 187451 which is 54.23% above its average volume of 121539.

yearly top and bottom value

gensight biologics's stock is valued at €0.37 at 21:37 est, below its 52-week low of €0.38.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, gensight biologics's stock is considered to be overbought (>=80).

more news about gensight biologics (sight.pa).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 8 Feb 2024
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›